Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$1.33 - $2.59 $997 - $1,942
-750 Closed
0 $0
Q3 2021

Nov 10, 2021

BUY
$3.55 - $7.49 $2,662 - $5,617
750 New
750 $3,000

Others Institutions Holding ARDS

About Aridis Pharmaceuticals, Inc.


  • Ticker ARDS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,701,600
  • Description
  • Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...
More about ARDS
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.